Zobrazeno 1 - 10
of 29
pro vyhledávání: '"José Miguel Ferrari"'
Autor:
Andrea Lázaro Cebas, José Manuel Caro Teller, Carmen García Muñoz, Carlos González Gómez, José Miguel Ferrari Piquero, Carlos Lumbreras Bermejo, José Antonio Romero Garrido, Juana Benedí González
Publikováno v:
BMC Health Services Research, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background Patient education on pharmacological treatment could reduce readmissions. Our objective was to carry out a pharmacist intervention focused on providing information about high-risk medications to chronic patients and to analyse its
Externí odkaz:
https://doaj.org/article/f49b14ba5bae4a6899bced58d2d6280b
Autor:
Miguel Pedrera-Jiménez, Rafael M. Rubio, Óscar Pinar, María Ángeles Hernández-Ros, David Rial-Crestelo, José Miguel Ferrari, Federico Pulido, José Manuel Caro-Teller, Pablo Serrano, Elena Ana López-Jiménez, Víctor Quirós-González, Noelia García-Barrio, José Luis Bernal, Carlos Martín-Jurado
Publikováno v:
Enfermedades Infecciosas Y Microbiologia Clinica
The COVID-19 pandemic has affected the care of patients with other diseases. Difficulty in access to healthcare during these months has been especially relevant for persons with HIV infection (PWH). This study therefore sought to ascertain the clinic
Autor:
Dolores Canales-Siguero, Carmen García-Muñoz, Pilar Quijada Fraile, Montserrat Morales Conejo, José Miguel Ferrari-Piquero, Elena Martín-Hernández
Publikováno v:
Medicina Clínica. 159:380-384
Autor:
Dolores Canales-Siguero, Carmen García-Muñoz, Pilar Quijada Fraile, Montserrat Morales Conejo, José Miguel Ferrari-Piquero, Elena Martín-Hernández
Publikováno v:
Medicina Clínica (English Edition). 159:380-384
Autor:
Susana Cortijo-Cascajares, Ana Cristina Cercós-Lletí, Sara Ortiz-Pérez, José Manuel Caro-Teller, José Miguel Ferrari-Piquero
Publikováno v:
Journal of Oncology Pharmacy Practice. 29:290-298
Objective To study immune-related adverse events (irAEs) in non-small cell lung cancer (NSCLC) patients treated with nivolumab, as well as to assess whether these reactions could be predictors of further effectiveness of therapy. Methods Retrospectiv
Autor:
Carmen Garcia-Muñoz, Jose Manuel Caro-Teller, Pedro Pablo Rodríguez Quesada, Almudena Añino Alba, José Miguel Ferrari Piquero, María Luisa Ibarra Mira
Publikováno v:
J Pharm Technol
Background: A significant percentage of hospital readmissions within 30 days of discharge are a result of avoidable drug-related problems. Stratifying patients according to readmission risk is key to pharmaceutical intervention (PI) design strategies
Autor:
Miguel Ángel, Bruni-Montero, José Manuel, Caro-Teller, José Antonio, Hernández-Ramos, Cristian, Rosas-Espinoza, Dolores, Canales-Siguero, José Miguel, Ferrari-Piquero
Publikováno v:
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 46(1)
The combination of selective serotonin reuptake inhibitors with rivaroxaban may result in a dual interaction (pharmacokinetic and pharmacodynamic) depending on the type of selective serotonin reuptake inhibitor employed (CYP3A4-inhibiting vs. non-CYP
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
José Antonio, Hernández-Ramos, José Manuel, Caro-Telle, Miguel Ángel, Bruni-Montero, Dolores, Canales-Siguero, José Miguel, Ferrari-Piquero
Publikováno v:
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 45(6)
The literature has described the interaction between valproic acid and carbapenems. This interaction leads to decreases in plasma concentrations of valproic acid. The main objectives of this study were to assess its relevance in clinical practice, to
Autor:
Carmen Garcia-Muñoz, José Miguel Ferrari Piquero, Miguel Angel Granados Ruíz, Dolores Canales Siguero, Francisco Martínez de la Torre
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics. 46:862-864
What is known and objective In paediatrics, evidence regarding the treatment of viral myocarditis using interferon beta-1B is restricted to four children older than two years and there are no reported cases of infants. The objective was to describe t